GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex (cannabidiol)

Date: 
Mon, 2016-03-14 (All day)

 

"The results of this Epidiolex pivotal trial are important and exciting as they represent the first placebo-controlled evidence to support the safety and efficacy of pharmaceutical cannabidiol in children with Dravet Syndrome, one of the most severe and difficult-to-treat types of epilepsy," said Orrin Devinsky, MD, of New York University Langone's Comprehensive Epilepsy Center.

 

Click here to read more about the study